ACRS Upcoming Earnings (Q3 2023)
|Earnings Date:||Nov 06, 2023|
Current P/E* ratio: -4.38 | Price (Sep 29, 2023, EOD): $6.85
*The P/E ratio (price-to-earnings ratio) is a financial metric used to assess a company's stock valuation. It is calculated by dividing the stock price by its earnings per share. A higher ratio suggests higher investor expectations, while a lower ratio may indicate undervaluation. It helps investors evaluate potential investments, but it's essential to consider other factors too.
Last 3 Quarters for ACRS Premium
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of... ACRS Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.